Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer's disease.
暂无分享,去创建一个
Francesco C Stingo | Marina Vannucci | Kim-Anh Do | David Ames | James D Doecke | Colin L Masters | Alan Rembach | M. Vannucci | R. Martins | C. Masters | K. Do | D. Ames | F. Stingo | S. L. Macaulay | A. Rembach | T. Ryan | J. Doecke | W. Wilson | Christine Peterson | Ralph N Martins | Timothy M Ryan | William J Wilson | S Lance Macaulay | Christine Peterson | S. Macaulay | William J. Wilson
[1] Li Yao,et al. Structural Interactions within the Default Mode Network Identified by Bayesian Network Analysis in Alzheimer’s Disease , 2013, PloS one.
[2] Jing Yu,et al. Bayesian Network Analysis Reveals Alterations to Default Mode Network Connectivity in Individuals at Risk for Alzheimer's Disease , 2013, PLoS ONE.
[3] P. Bjorkman,et al. Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptor , 1994, Nature.
[4] Sid O'Bryant,et al. Developing novel blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.
[5] M. Tadesse,et al. Identification of Functional Modules by Integration of Multiple Data Sources Using a Bayesian Network Classifier , 2014, Circulation. Cardiovascular genetics.
[6] Tirunelveli S. Ramalingam,et al. Interaction of class I human leukocyte antigen (HLA-I) molecules with insulin receptors and its effect on the insulin-signaling cascade. , 1997, Molecular biology of the cell.
[7] Hilkka Soininen,et al. Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression. , 2014, Journal of Alzheimer's disease : JAD.
[8] H. Kiiveri,et al. A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study , 2014, Molecular Psychiatry.
[9] C. Rowe,et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.
[10] T. Tapiola,et al. Biological Markers for Alzheimer's Disease , 2001 .
[11] Christine B Peterson,et al. Bayesian Inference of Multiple Gaussian Graphical Models , 2015, Journal of the American Statistical Association.
[12] Justin Bedo,et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.
[13] W. Robberecht,et al. Beta-2 microglobulin is important for disease progression in a murine model for amyotrophic lateral sclerosis , 2013, Front. Cell. Neurosci..
[14] K. Blennow,et al. Fluid biomarkers in Alzheimer’s disease – current concepts , 2013, Molecular Neurodegeneration.
[15] C. Rowe,et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.
[16] M. Bolognesi,et al. Class I Major Histocompatibility Complex, the Trojan Horse for Secretion of Amyloidogenic β2-Microglobulin* , 2013, The Journal of Biological Chemistry.
[17] Blaine R. Roberts,et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease , 2014, Alzheimer's & Dementia.
[18] Yu-Chun Lin,et al. ' s response to reviews Title : Identifying Significant Genetic Regulatory Networks in the Prostate Cancer from Microarray Data Based on Transcription Factor Analysis and Conditional Independency , 2009 .
[19] S. Lehmann,et al. Biomarkers of Alzheimer's disease: the present and the future. , 2013, Revue neurologique.
[20] L. Tan,et al. Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.
[21] Michael W. Weiner,et al. The future of blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.
[22] Shyam Visweswaran,et al. The application of network label propagation to rank biomarkers in genome-wide Alzheimer’s data , 2014, BMC Genomics.
[23] S. Radford,et al. Direct three-dimensional visualization of membrane disruption by amyloid fibrils , 2012, Proceedings of the National Academy of Sciences.
[24] C. Rowe,et al. Plasma apolipoprotein E and Alzheimer disease risk , 2011, Neurology.
[25] L. Risch,et al. Factors Other than the Glomerular Filtration Rate That Determine the Serum Beta-2-Microglobulin Level , 2013, PloS one.
[26] D. Stevenson,et al. Polyphenolic phytochemicals – just antioxidants or much more? , 2007, Cellular and Molecular Life Sciences.
[27] Tao Wang,et al. The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease , 2014, International journal of geriatric psychiatry.
[28] S. Radford,et al. Fibril fragmentation in amyloid assembly and cytotoxicity , 2010, Prion.
[29] N. Faux,et al. An anemia of Alzheimer's disease , 2014, Molecular Psychiatry.
[30] Marina Vannucci,et al. Inferring metabolic networks using the Bayesian adaptive graphical lasso with informative priors. , 2013, Statistics and its interface.
[31] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[32] H. Zetterberg. Unresolved questions in Alzheimer's research: will biomarkers help? , 2014, Biomarkers in medicine.
[33] David M. Holtzman,et al. Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease , 2014, Biological Psychiatry.
[34] S. Radford,et al. Fibril Fragmentation Enhances Amyloid Cytotoxicity*♦ , 2009, The Journal of Biological Chemistry.
[35] Alfred A. Bartolucci,et al. An examination of Bayesian statistical approaches to modeling change in cognitive decline in an Alzheimer's disease population , 2009, Math. Comput. Simul..
[36] Guanghua Xiao,et al. A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI , 2011, PloS one.
[37] Blaine R. Roberts,et al. Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.
[38] P. Thompson,et al. A Systematic Review of Biomarkers for Disease Progression in Alzheimer's Disease , 2014, PloS one.
[39] C S Cardoso,et al. HFE, the MHC and hemochromatosis: paradigm for an extended function for MHC class I. , 2003, Tissue antigens.
[40] C. Masters,et al. Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. , 2012, Journal of Alzheimer's disease : JAD.
[41] C. Rowe,et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. , 2010, Journal of Alzheimer's disease : JAD.
[42] Thomas L. Williams,et al. Membrane and surface interactions of Alzheimer’s Aβ peptide – insights into the mechanism of cytotoxicity , 2011, The FEBS journal.
[43] Jinglong Wu,et al. Network-Based Biomarkers in Alzheimer’s Disease: Review and Future Directions , 2014, Front. Aging Neurosci..
[44] Blaine R. Roberts,et al. Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. , 2013, Biomarkers in medicine.
[45] C. Rowe,et al. Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. , 2014, Journal of Alzheimer's disease : JAD.
[46] Xiaojing Sui,et al. Cerebrospinal fluid biomarkers of Alzheimer’s disease , 2014, Neuroscience Bulletin.
[47] Walter J Koroshetz,et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. , 2012, Archives of neurology.
[48] A. Fleisher,et al. Altered default mode network connectivity in alzheimer's disease—A resting functional MRI and bayesian network study , 2011, Human brain mapping.